The round was led by early-stage life science investors, Deepbridge Capital LLP, with significant participation from MAINStream, OION, SAIC and existing investors. This investment will enable the team at FluoretiQ to produce trial units of their first NANOPLEX™ product, a 15-minute UTI (urinary tract infection) diagnostic device.
Bristol's FluoretiQ announces the closure of £1.1 million funding round
Press release issued: 21 February 2022
University of Bristol spin-out, FluoretiQ, has today announced the completion of a £1.1 million, pre-series A investment. Their pioneering NANOPLEX technology is a 15-minute proprietary diagnostic platform for bacterial infections.